Arbutus Biopharma Reports Director Changes and Compensation

Ticker: ABUS · Form: 8-K · Filed: 2024-10-11T00:00:00.000Z

Sentiment: neutral

Topics: corporate-governance, executive-compensation, filing-update

Related Tickers: ABUS

TL;DR

Arbutus Biopharma (ABUS) filed an 8-K detailing board changes and executive comp. Watch for updates.

AI Summary

Arbutus Biopharma Corp. filed an 8-K on October 11, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also includes financial statements and exhibits, indicating ongoing corporate activities and potential shifts in leadership or financial reporting.

Why It Matters

Changes in a company's board and executive compensation can signal strategic shifts or governance adjustments that may impact future performance and investor confidence.

Risk Assessment

Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may affect company strategy and future performance.

Key Players & Entities

Arbutus Biopharma Corp. (company) — Registrant
October 11, 2024 (date) — Date of earliest event reported
701 Veterans Circle (location) — Business and mailing address
Warminster, Pennsylvania (location) — Business and mailing address
TEKMIRA PHARMACEUTICALS Corp (company) — Former company name

FAQ

What specific changes were made to the board of directors?

The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item of information, but the specific details of these changes are not provided in the excerpt.

What are the details of the compensatory arrangements for certain officers?

The filing lists "Compensatory Arrangements of Certain Officers" as an item of information, but the specific details of these arrangements are not included in the provided text.

When was Arbutus Biopharma Corporation incorporated?

Arbutus Biopharma Corporation was incorporated in British Columbia, Canada.

What is Arbutus Biopharma's fiscal year end?

Arbutus Biopharma's fiscal year ends on December 31st.

What is the SIC code for Arbutus Biopharma Corp?

The Standard Industrial Classification (SIC) code for Arbutus Biopharma Corp. is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001447028-24-000084.txt : 20241011 0001447028-24-000084.hdr.sgml : 20241011 20241011160736 ACCESSION NUMBER: 0001447028-24-000084 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241011 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241011 DATE AS OF CHANGE: 20241011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 980597776 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 241367642 BUSINESS ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 701 VETERANS CIRCLE CITY: WARMINSTER STATE: PA ZIP: 18974 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 8-K 1 abus-20241011.htm 8-K abus-20241011 FALSE 0001447028 701 Veterans Circle Warminster Pennsylvania 0001447028 2024-10-11 2024-10-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM  8-K   CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported):  October 11, 2024 Arbutus Biopharma Corp oration (Exact name of registrant as specified in its charter)   British Columbia, Canada   001-34949   98-0597776 (State or other jurisdiction of incorporation)   (Commission File Number)   (IRS Employer Identification No.)   701 Veterans Circle Warminster , Pennsylvania   18974 (Address of principal executive offices)   (Zip Code)   ( 267 ) 469-0914 Registrant’s telephone number, including area code     (Former name or former address, if changed since last report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Shares, without par value   ABUS   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    o Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed, Michael J. Sofia announced his retirement as Chief Sci